PROCEPT BioRobotics (NASDAQ:PRCT) used its 2026 Analyst Day to outline what management characterized as a large, underpenetrated opportunity in benign prostatic hyperplasia (BPH), a developing ...

PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but ...

Q4 2025 earnings call recap: revenue, procedure growth, 2026 guidance, margin drivers & risks from sales changes—read now.

Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

Ratings for PROCEPT BioRobotics (NASDAQ:PRCT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...

We recently published a list of the 10 Best Robotics Stocks to Buy According to Billionaires. In this article, we are going to take a look at where PROCEPT BioRobotics Corporation (NASDAQ:PRCT) stands ...